ADJUVANCE TECHNOLOGIES INC.
Synthetic saponin vaccine adjuvants, specifically engineered QS-21 analogs with improved potency and reduced toxicity
Follows are private to you and power your alerts
Updated · adjuvancetechnologies.com
- Sector
- Biotech
- Headquarters
- Lincoln, NE
- Latest Form D
- $10.7M, Sep 2019
- Total capital
- $16.4M
- Federal grants
- $3M
- 3 awards · 2017–2018
- Rank in peer group#176 of 326
- Private capital raised
- $11.7M
- 2 Form D · last Sep 2019
- 85 months since last filing
- Federal contracts
- $1.7M
- 2 awards · Health and Human S
- Rank in Biotech#147 of 4373
- Granted patents
- 3
- 36 pending · first 2022
- Rank in peer group#45 of 326
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$10.7M
- Federal contractHealth and Human S · Igf::ot::igf Preclinical Development Of Semisynthetic Saponin Immunological Adjuvant TITERQUIL-1055 In The Context Of An Influenza Vaccine. New Award$1.5M
- Federal grantHealth and Human S · Phase II · Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil$743K
- Federal contractHealth and Human S · Igf::ot::igf Determining The Impact Of Semisynthetic Saponin Immunologic Adjuvant TITERQUIL-1055 On Influenza Vaccine Immunogenicity And Stability$223K
- Federal grantHealth and Human S · Phase II · Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil$1.5M
- Federal grantHealth and Human S · Phase II · Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil$757K
- Private capital raisedForm D · SEC · 1st filing$1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#45 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- J. Tyler MartinResearcherExecutive Officer, DirectorLinked by 2 patents
- Tyler MartinResearcherExecutive Officer, DirectorLinked by 2 patents
- Christopher FrigonExecutive Officer, DirectorNamed in SEC Form D filings
- Govind RagupathiDirectorNamed in SEC Form D filings
- Gregory PolandDirectorNamed in SEC Form D filings
- Isaac ChengDirectorNamed in SEC Form D filings
Show all 12 people
- Jeffrey GardnerExecutive Officer, DirectorNamed in SEC Form D filings
- John GalloDirectorNamed in SEC Form D filings
- Ken KelleyDirectorNamed in SEC Form D filings
- Mary GinDirectorNamed in SEC Form D filings
- Phil LivingstonDirectorNamed in SEC Form D filings
- Stephen DillyDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 39- GrantedVaccines, Vaccine Priming, And Antigen Dose SparingUSPTOUS 12,741,022
- GrantedVaricella ZosterUSPTOUS 12,673,101
- PendingVaccinesUSPTOApplication 18552863
Show all 39 patent records
- Vaccines, Vaccine Priming, And Antigen Dose SparingSep 22, 2026 · US 12,741,022Granted
- Varicella ZosterJul 7, 2026 · US 12,673,101Granted
- VaccinesApr 30, 2026 · Application 18552863Pending
- Adjuvant Compounds And FormulationsJan 23, 2025 · Application 18708417Pending
- Triterpene Saponin Synthesis, Intermediates And Adjuvant CombinationsNov 9, 2023 · Application 18188101Pending
- Vaccines, Vaccine Priming, And Antigen Dose SparingAug 24, 2023 · Application 18011064Pending
- Adjuvant Compounds, Salt Forms, And FormulationsApr 27, 2023 · Application 17910224Pending
- Triterpene Saponin AnaloguesJun 16, 2022 · Application 17687094Pending
- Triterpene Saponin AnaloguesMay 10, 2022 · US 11,324,821Granted
- Triterpene Saponin Synthesis, Intermediates And Adjuvant CombinationsSep 30, 2021 · Application 16604867Pending
- Triterpene Saponin AnaloguesMay 28, 2020 · Application 16608352Pending
- Improved Vaccine Priming And Antigen Dose SparingApplication 63072872Pending
- Vaccine Priming And Antigen Dose SparingApplication 63058874Pending
- Vaccine Antigen Dose SparingApplication 63041035Pending
- Adjuvant Compounds And Salt Forms ThereofApplication 62993583Pending
- Varicella ZosterApplication 62930727Pending
- Triterpene Saponin AnaloguesApplication PCTUS2018055828Pending
- Triterpene Saponin AnaloguesApplication PCTUS2018029333Pending
- Triterpene Saponin Synthesis, Intermediates And Adjuvant CombinationsApplication PCTUS2018027462Pending
- Triterpene Saponin AnaloguesApplication 62573501Pending
- Triterpene Saponin AnaloguesApplication 62572857Pending
- Triterpene Saponin AnaloguesApplication 62492608Pending
- Triterpene Saponin AnaloguesApplication 62489572Pending
- Triterpene Saponin AnaloguesApplication 62489556Pending
- Triterpene Saponin Synthesis, Intermediates And Adjuvant CombinationsApplication 62489546Pending
- Triterpene Saponin Synthesis, Intermediates And Adjuvant CombinationsApplication 62488287Pending
- Triterpene Saponin Synthesis, Intermediates And Adjuvant CombinationsApplication 62485260Pending
- Triterpene Saponin AnaloguesApplication PCTUS2016060564Pending
- Triterpene SaponinsApplication 62252296Pending
- Adjuvant Compounds And FormulationsApplication PCTUS2022049255Pending
- Adjuvant Compounds And FormulationsApplication 63351057Pending
- VaccinesApplication PCTUS2022024594Pending
- Adjuvant Compounds And FormulationsApplication 63277001Pending
- VaccinesApplication 63221878Pending
- Vaccines, Vaccine Priming, And Antigen Dose SparingApplication PCTUS2021037907Pending
- Saponin Adjuvant Compounds And TLR4 Agonists And AntagonistsApplication 63174910Pending
- Adjuvant Compounds, Salt Forms, And FormulationsApplication PCTUS2021023591Pending
- Varicella ZosterApplication PCTUS2020058859Pending
- Adjuvant Compounds, Salt Forms, And FormulationsApplication 63094143Pending
Related companies, and why
- INTEGRATED RESEARCH ASSOCIATES, LLCSimilar federal contract value in Biotech · $1.8M in contracts
- LUCERNA INCSimilar federal contract value in Biotech · $1.8M in contracts
- Blaze Bioscience, Inc.Similar federal contract value in Biotech · $1.7M in contracts
- INGENIOUS TARGETING LABORATORY INC.Similar federal contract value in Biotech · $1.7M in contracts
- SCRIBE BIOSCIENCES, INC.Similar federal contract value in Biotech · $1.7M in contracts
- Strand Therapeutics Inc.Similar federal contract value in Biotech · $1.6M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .